Impact of angiotensin receptor blockers (ARB) versus other antihypertensive medication on blood pressure in patients on dialysis: a meta-analysis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085141" target="_blank" >RIV/00023001:_____/24:00085141 - isvavai.cz</a>

Výsledek na webu

<a href="https://indianjnephrol.org/impact-of-angiotensin-receptor-blockers-arb-versus-other-antihypertensive-medication-on-blood-pressure-in-patients-on-dialysis-a-meta-analysis/" target="_blank" >https://indianjnephrol.org/impact-of-angiotensin-receptor-blockers-arb-versus-other-antihypertensive-medication-on-blood-pressure-in-patients-on-dialysis-a-meta-analysis/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.25259/ijn_365_23" target="_blank" >10.25259/ijn_365_23</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of angiotensin receptor blockers (ARB) versus other antihypertensive medication on blood pressure in patients on dialysis: a meta-analysis

Popis výsledku v původním jazyce

Introduction: Hypertension is an important factor driving mortality among dialysis patients. Angiotensin-II receptor blocker (ARB) has been effective similarly to angiotensin-converting enzymes (ACEs) but with a low incidence of side effects. Methodology: The meta-analysis included all published studies that investigated the effect of ARB on the hypertension in adult dialysis patients (≥18 years). Data extraction was guided by a predetermined checklist. Data sources of the retrieved studies were PubMed, MEDLINE, ScienceDirect, SCOPUS, Cochrane, Web of knowledge, and Google Scholar were systematically searched until February 2023. Using the RevMan 5 software, the mean difference for systolic and diastolic BP (SBP and DBP) and the risk ratio (RR) of the adverse events (AEs) were pooled from the selected studies. The random-effects model was used to compare the difference in the pre-and post-dialysis of the SBP and DBP. Data analyses were performed from December 2022 to February 2023. The primary outcome was the reduction in SBP and DBP in dialysis hypertensive patients who were on anti-hypertensive agents, and the secondary outcome was assessment of AE associated with the drug after dialysis (PROSPERO Registration: CRD42022355369). Results: The initial search yielded 1,679 records, of which 84 studies underwent full-text evaluation, which identified 13 studies and 1,462 patients. The pooled standard MD for losartan with other antihypertensive agents, where the pre-dialysis SBP was 0.17 (95% confidence interval [CI]: −0.21–0.55) and the post-dialysis was 0.35 (95% CI: −0.17–1.02); yet, both are statistically non-significant, implies that there was no difference between Losartan and ARB drugs regarding the effect on the SBP. Diastolic BP for predialysis was −0.01 (95% CI: −0.65–0.63) and post-dialysis was 0.03 (95% CI: −0.24−0.30) and statistically non-significant. AEs by the ARB agents were lower compared to other anti-antihypertensive agents (relative risk [RR]: 1.01; 95% CI: 0.59–1.75) and statistically non-significant. Conclusion: This systematic review and meta-analysis of RCT demonstrated that ARB and other anti-hypertensive medications had similar impacts on the treatment of hypertension. © 2024 Indian Journal of Nephrology.

Název v anglickém jazyce

Impact of angiotensin receptor blockers (ARB) versus other antihypertensive medication on blood pressure in patients on dialysis: a meta-analysis

Popis výsledku anglicky

Introduction: Hypertension is an important factor driving mortality among dialysis patients. Angiotensin-II receptor blocker (ARB) has been effective similarly to angiotensin-converting enzymes (ACEs) but with a low incidence of side effects. Methodology: The meta-analysis included all published studies that investigated the effect of ARB on the hypertension in adult dialysis patients (≥18 years). Data extraction was guided by a predetermined checklist. Data sources of the retrieved studies were PubMed, MEDLINE, ScienceDirect, SCOPUS, Cochrane, Web of knowledge, and Google Scholar were systematically searched until February 2023. Using the RevMan 5 software, the mean difference for systolic and diastolic BP (SBP and DBP) and the risk ratio (RR) of the adverse events (AEs) were pooled from the selected studies. The random-effects model was used to compare the difference in the pre-and post-dialysis of the SBP and DBP. Data analyses were performed from December 2022 to February 2023. The primary outcome was the reduction in SBP and DBP in dialysis hypertensive patients who were on anti-hypertensive agents, and the secondary outcome was assessment of AE associated with the drug after dialysis (PROSPERO Registration: CRD42022355369). Results: The initial search yielded 1,679 records, of which 84 studies underwent full-text evaluation, which identified 13 studies and 1,462 patients. The pooled standard MD for losartan with other antihypertensive agents, where the pre-dialysis SBP was 0.17 (95% confidence interval [CI]: −0.21–0.55) and the post-dialysis was 0.35 (95% CI: −0.17–1.02); yet, both are statistically non-significant, implies that there was no difference between Losartan and ARB drugs regarding the effect on the SBP. Diastolic BP for predialysis was −0.01 (95% CI: −0.65–0.63) and post-dialysis was 0.03 (95% CI: −0.24−0.30) and statistically non-significant. AEs by the ARB agents were lower compared to other anti-antihypertensive agents (relative risk [RR]: 1.01; 95% CI: 0.59–1.75) and statistically non-significant. Conclusion: This systematic review and meta-analysis of RCT demonstrated that ARB and other anti-hypertensive medications had similar impacts on the treatment of hypertension. © 2024 Indian Journal of Nephrology.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Indian Journal of Nephrology

ISSN

0971-4065

e-ISSN

1998-3662

Svazek periodika

34

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

IN - Indická republika

Počet stran výsledku

11

Strana od-do

431-441

Kód UT WoS článku

001356594300003

EID výsledku v databázi Scopus

2-s2.0-85203137003